Register

Login

Vet Times logo
+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
    • Crossword
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • All Jobs
  • Your ideal job
  • Post a job
  • Career Advice
  • Students
About
Contact Us
For Advertisers
NewsClinicalJobs
Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcastsDigital EditionCrossword

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

All Jobs

Your ideal job

Post a job

Career Advice

Students

More

All More content

Videos

Podcasts

Digital Edition

Crossword


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2025

IPSO_regulated

22 Jun 2020

Sector-first therapy for severe equine asthma

New product has been designed to allow medication to be inhaled deep into the lungs of horses suffering severe asthma.

author_img

Paul Imrie

Job Title



Sector-first therapy for severe equine asthma

EquiHaler

The first inhaled treatment approved for horses suffering severe equine asthma is now available in the UK and Ireland.

Aservo EquiHaler, a ciclesonide inhalation solution from Boehringer Ingelheim, has been in development for more than 10 years and has involved collaboration between the firm’s animal health and human pharma divisions.

The latter’s Respimat inhaler technology, which uses the trademarked Soft Mist technology, has now been integrated into the Aservo EquiHaler, which will allow medication to be inhaled deep into an affected horse’s lungs.

Commitment

Marc Laemmer, head of equine in the UK and Ireland, said: “It’s another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.

“We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available.

“The launch is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I’m excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets.”

Award

Aservo EquiHaler’s active ingredient, ciclesonide, is a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly seen with systemic corticosteroids.

The product has been manufactured from 50% recycled materials, and does not use a propellant, so does not feature harmful greenhouse gases.

Featuring an ergonomic handle and dosing lever for ease of user handling, as well as a nostril adaptor for the horse’s nostril, the product won the Red Dot Award for Product Design.